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Objectives: Combination microbicide vaginal rings may be more effective than single microbicide rings at
reducing/preventing sexual transmission of HIV. Here, we report the pre-clinical development and macaque
pharmacokinetics of matrix-type silicone elastomer vaginal rings containing dapivirine and darunavir.
Methods: Macaque rings containing 25 mg dapivirine, 100 mg dapivirine, 300 mg darunavir or 100 mg
dapivirine+300 mg darunavir were manufactured and characterized by differential scanning calorimetry.
In vitro release was assessed into isopropanol/water and simulated vaginal fluid. Macaque vaginal fluid and
blood serum concentrations for both antiretrovirals were measured during 28 day ring use. Tissue levels were
measured on day 28. Ex vivo challenge studies were performed on vaginal fluid samples and IC50 values were
calculated.
Results: Darunavir caused a concentration-dependent reduction in the dapivirine melting temperature in both
solid drug mixes and in the combination ring. In vitro release from rings was dependent on drug loading, the
number of drugs present and the release medium. In macaques, serum concentrations of both microbicides
were maintained between 101 and 102 pg/mL. Vaginal fluid levels ranged between 103 and 104 ng/g and
between 104 and 105 ng/g for dapivirine and darunavir, respectively. Both dapivirine and darunavir showed
very similar concentrations in each tissue type; the range of drug tissue concentrations followed the general
rank order: vagina (1.8×103–3.8×103 ng/g) .cervix (9.4×101–3.9×102 ng/g) .uterus (0–108 ng/g) .rectum
(0–40 ng/g). Measured IC50 values were .2 ng/mL for both compounds.
Conclusions: Based on these results, and in light of recent clinical progress of the 25 mg dapivirine ring, a com-
bination vaginal ring containing dapivirine and darunavir is a viable second-generation HIV microbicide
candidate.
Keywords: HIV microbicides, silicone elastomer vaginal rings, cynomolgus macaques, pharmacokinetics
Introduction
Over the past 20 years, various vaginally administered products
have been evaluated as topical microbicides for reduction or pre-
vention of sexual transmission of HIV type 1 (HIV-1), although
none has yet reached market. More recently, owing to lack of effi-
cacy, focus has shifted away from microbicide compounds with
non-specific mechanisms of action and towards more potent
antiretroviral (ARV) drugs, similar to those used in highly active
antiretroviral therapy (HAART) and targeted at specific steps in
the HIV replication cycle. Various lead candidate microbicide
products containing a single ARV drug are now progressing
through clinical development, including a dapivirine-releasing
vaginal ring,1–3 a tenofovir-releasing vaginal ring4 and an aque-
ous tenofovir gel.5 Following the combinatorial drug approach
established with HAART,6 next-generation microbicides will also
likely be combination drug products or multipurpose prevention
technologies, containing multiple ARV drugs or a combination of
ARV, contraceptive and/or antimicrobial agents, respectively.7
There are good reasons for pursuing combination microbicides.
Compared with a single ARV drug, they may offer: (i) increased
breadth of activity against emerging resistant viral strains;
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(ii) lower clinical concentrations for efficacy due to additive or
synergistic effects; and (iii) greater protection through targeting
of multiple stages in the virus replication cycle.8 To date, only
a limited number of combination ARV microbicide strategies
have been reported, including three vaginal ring products9 –11
and several gel formulations12,13 (Table 1).
Here, we report the pre-clinical development of a silicone
elastomer matrix-type vaginal ring containing a combination of
dapivirine and darunavir ethanolate (also known as TMC114;
hereafter referred to simply as darunavir). Dapivirine is an experi-
mental non-nucleoside reverse transcriptase inhibitor (NNRTI)
currently undergoing Phase III clinical testing in Africa as an HIV
microbicide in the format of a 25 mg dapivirine-loaded silicone
elastomer matrix-type vaginal ring.1 – 3 Darunavir is a second-
generation protease inhibitor used in combination with other
ARVs in the treatment of HIV infection. Protease inhibitors inhibit
the HIV protease enzyme required to produce mature infectious
virus particles by cleaving structural proteins and enzymes from
their precursors. Their high potency within HAART regimens and
the relatively high genetic barrier to the emergence of resistant
HIV strains (compared with other ARVs) suggest they have good
potential as microbicides, administered alone or in combination
with other ARVs.14,15
Materials and methods
Materials
Medical grade, addition-cure, silicone elastomer two-part kit (LSR9-
9509-30; also known as DDU-4320) was supplied by Nusil Silicone
Technology Inc. (Carpinteria, CA, USA). Darunavir and dapivirine were
kindly provided by Janssen Research and Development (Beerse, Belgium)
and the International Partnership for Microbicides (IPM; Silver Spring, MD,
USA), respectively. HPLC-grade acetonitrile, isopropanol (IPA), methanol,
dichloromethane, trifluoroacetic acid (TFA) and 19-norethindrone were
obtained from Sigma–Aldrich (Gillingham, UK). Simulated vaginal fluid
(SVF; pH 4.2) was prepared using analytical grade reagents according to a
method described previously.16 Deionized water, resistivity .18 mV/cm2,
was obtained from a Millipore Direct-Q3 UV Ultrapure water system
(Watford, UK).
Ring manufacture
Macaque-sized, matrix-type, silicone elastomer vaginal rings (25 mm
outer diameter and 6 mmcross-sectional diameter9,17) containing various
loadings of dapivirine (25 and 100 mg), darunavir (300 mg) and their
combination (100 mg dapivirine+300 mg darunavir) were manufactured
by reaction injection moulding on a custom laboratory-scale ring
manufacturing machine. For batch manufacture of each ring formulation,
the required quantities of dapivirine and darunavir were added to both
parts A and B of the silicone elastomer system in polypropylene containers.
After mixing at 2000 rpm for 5 min (SpeedMixerTM DAC 150.1 FVZ-K,
Synergy Devices Ltd, UK), the containers were degassed in a vacuum
chamber (0.143 Torr held for 30 min; LACO Technology, Salt Lake City,
UT, USA), and then stored sealed at 48C for 60 min. Parts A and B of the
silicone/drug mixture were combined in a 1:1 ratio and mixed (3000 rpm
for 30 s) before being injected into pre-heated (808C), precision-
engineered, stainless steel, vaginal ring moulds and cured for 3 min.
Each ring weighed 1.8 g.
Thermal analysis by differential scanning
calorimetry (DSC)
Samples of micronized dapivirine, non-micronized darunavir and mixtures
of the two drugs in various proportions were prepared for DSC analysis.
Each mixture was mixed thoroughly, first by hand using a spatula
and then in a SpeedmixerTM at 3000 rpm. Powder samples were analysed
by DSC (TA Instruments 2920 modulated DSC) in standard heating ramp
mode. Approximately 5–10 mg of each sample was accurately weighed
into an aluminium pan and heated from 20 to 2508C at a rate of 108C
per min alongside an empty reference pan. For each sample, the following
parameters were noted for any melting transitions that were observed:
onset temperature (8C), peak temperature (8C) and enthalpy (DH, J/g). A
minimum of four replicates were used to calculate mean values for each
sample mixture. DSC analysis was similarly performed on silicone elasto-
mer samples loaded with various concentrations and ratios of dapivirine
only, darunavir only and dapivirine+darunavir in order to characterize
the nature of the drugs in the rings.
In vitro release testing
In vitro release of dapivirine and darunavir from the single active com-
pound and combination rings into both IPA/water (1:1) and SVF media
was assessed over a continuous 28 day period. An IPA/water mixture
has been widely used for in vitro release testing of silicone elastomer vagi-
nal rings containing poorly water-soluble drugs, since its greater solvating
capacity offers sink conditions.1,9,11,18 Individual rings were placed into
wide-necked screw-capped 250 mL glass flasks (Duranw GLS 80w) con-
taining 100 mL IPA/water (1:1) or SVF (n¼4). The flasks were sealed and
placed in a rotating orbital incubator (Infors HT Unitron, Switzerland; 378C,
60 rpm, throw 25 mm). After 24 h (+15 min), each flask was removed
from the incubator and a 2 mL sample of release medium was retained
for HPLC analysis. The remaining release medium was discarded and
replaced with a fresh 50 mL aliquot of either IPA/water or SVF. Sampling
and release medium replacement was conducted daily except for week-
ends, when the release medium volume was doubled and the daily sam-
pling routine was restarted again on the Monday. The quantities of
dapivirine and darunavir released from the rings were determined using
HPLC with UV detection at 257 nm. A 10 mL aliquot of each sample was
injected onto a Luna 5 mm C18(2) 100 A˚ column (150×4.6 mm;
Phenomenex, Cheshire, UK) maintained at 308C. HPLC analysis was con-
ducted in isocratic mode with a mobile phase comprising 0.1% TFA in
water (45%) and methanol (55%) at a flow rate of 1 mL/min. Under
these conditions, dapivirine and darunavir displayed retention times of
12.0 and 10.5 min, respectively. Standard solutions of dapivirine and dar-
unavir in methanol (0.1–100 mg/mL) were used to construct a linear cali-
bration plot for each analyte (R2¼0.9949 and 0.9929 for dapivirine and
darunavir, respectively) and drug concentrations were determined for
each sample. Daily (or weekend) release values were subsequently calcu-
lated and used to plot daily and cumulative release versus time.
Table 1. Combination HIV microbicide approaches reported in the
literature
Microbicide combination Formulation Reference
Carrageenan+MIV-150 gel 32
Dapivirine+maraviroc ring 11
Dapivirine+tenofovir ring 33
Tenofovir+IQP-0528 gel 34,35
Tenofovir+UC781 gel 36
Stampidine+PHI-443 gel 37
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Pharmacokinetic study in macaques
A pharmacokinetic study in adult female cynomolgus macaques (weight
range 3–7 kg) was performed at Commissariat a` l’Energie Atomique
(CEA), IDMIT infrastructure. Non-human primates (which include Macaca
fascicularis) are used at the CEA in accordance with French national
regulations and under the supervision of national veterinary inspectors
(CEA Permit Number A 92-032-02). The CEA complies with the Standards
for Human Care and Use of Laboratory Animals, of the Office for
Laboratory Animal Welfare (OLAW, USA) under OLAWAssurance number
#A5826-01. All experimental procedures were conducted according to
European guidelines for animal care (European directive 86/609, ‘Journal
Officiel des Communaute´s Europe´ennes’, L358, December 18, 1986). The
use of non-human primates at the CEA is also in conformity with the
recommendations of the newly published European Directive (2010/63,
recommendation No. 9). The animals were used under the supervision
of the veterinarians in charge of the animal facility. This study was scien-
tifically reviewed and approved by the EU FP7 Combined Highly Active
Antiretroviral Microbicide (CHAARM) programme and was accredited
under statement numbers 10-062, by the ethics committee Comite´
d’Ethique en Expe´rimentation Animale du CEA registered under number
44 by the French Ministry of Research. Four animals were used per ring
treatment and there was no pre-treatment with Depo-Provera (medroxy-
progesterone acetate).9 Following atraumatic ring insertion into the
vagina under anaesthesia on day 0, blood (serum) and vaginal fluid
were collected at 8, 24 and 48 h and after 7, 14 and 28 days (Table 2).
Blood was sampled into either EDTA tubes (for haematology) or dry
tubes (for drug quantification). Vaginal fluid sampling was performed
using Weck-Celw spears (Medtronic Ophthalmics, Jacksonville, FL, USA)
based on a previously describedmethod.2 A sample collection set contain-
ing the Weck-Celw spear head plus a collection microtube was housed
within a sterile 50 mL polypropylene tube. Each sample collection tube
was pre-weighed and labelled for each animal. Sample collection sets con-
taining theWeck-Celw spear were stored on ice at between 2 and 88C until
sample collection. TheWeck-Celw spear was placed in the vaginal vault for
1–2 min to absorb the fluid. The spear head was then cut and placed into
the collection microtube. After closure of its lid, the microtube was placed
back into the corresponding outer tube. The stem of the spear was placed
into the outer tube and the sample collection set was placed back on ice.
Fluid samples were returned to the laboratory for processing within 2 h of
collection. The sample collection set was removed from ice, the exterior of
the tube cleaned and weighed on a fine balance. The collection tube con-
taining theWeck-Celw spear headswas removed and stored at –808C until
further analysis. Progesterone concentrations in serum were quantified
using a progesterone ELISA kit (RE52231, IBL International, Germany) at
baseline and on days 7, 14 and 28 to determine the phase of menstrual
cycle during ring placement. Animals were necropsied on day 28 and three
samples of various tissues (vagina, cervix, uterus, rectum, female genital
tract draining lymph nodes and distal lymph nodes) were taken and frozen
at –808C. Biological samples were shipped on dry ice to CEA Gif-sur-Yvette
for quantification of dapivirine and darunavir by HPLC tandem mass
spectrometry (HPLC-MS/MS.)
Quantification of dapivirine and darunavir
in biological samples
Dapivirine and darunavir were quantified in macaque vaginal fluid, serum
and tissue by ultra-performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS). Dapivirine-d11 and darunavir-d9 (Toronto
Research Chemicals, Canada) were used as internal standards. Vaginal
fluid and serum sample preparation was performed as previously
described.2 Frozen tissue samples (around 50 mg) from necropsied
animals were homogenized in 1 mL of ice-cold methanol/Tris 0.05 M/HCl
pH 5; 70/30 (v/v) containing internal standard, using a Precellys tissue
homogenizer (Bertin Technologies, France). Cellular debris was removed
by spinning at 20000 g for 15 min at 48C and transferring the supernatant
to a fresh tube. Samples were then evaporated to dryness at 408C with
a nitrogen stream in a Turbovap LV evaporator (Biotage, UK) and
re-suspended in 150 mL of initial mobile phase. The extract sample was
transferred to a vial, and a 20 mL aliquot was injected into the chromato-
graphic system. LC-MS/MS conditions were the same for the analysis
of vaginal fluid, serum and tissue samples. The calibration ranges for the
bioanalytical assays were 14–2000 pg/mL, 0.400–500 ng (i.e. 20–
25000 ng/g) and 1–2000 ng (i.e. 20–25000 ng/g) for dapivirine and
darunavir in serum, vaginal fluid and tissue samples, respectively. The
extract samplesmaintained at 48C in the autosampler were chromatogra-
phically separated using a Waters ACQUITY UPLCw System with an
ACQUITY UPLC BEH RP18 shield, 2.1×100 mm, 1.7 mm column and a
reversed phase gradient over a run time of 5 min. Initial conditions con-
sisted of mobile phase A (0.4% ammonia in water) and mobile phase B
(acetonitrile) at 70/30 (v/v) with a column temperature of 408C and a
flow rate of 0.400 mL/min. The gradient conditions ramped from 30% B
to 100% B between 1.0 and 2.0 min, then maintained up to 2.8 min,
ramped to 30% in 0.01 min and then maintained up to 5 min for
re-equilibration. The MS analysis was performed on a Waters XevoTM
TQ-MS mass spectrometer operated in positive ion electrospray
multiple-reaction monitoring mode (MRM) mode. Briefly, main tune para-
meters were as follows: capillary voltage was set up at 3 kV, source tem-
perature was 1508C, desolvation temperature was 3508C, cone gas flow
was 50 L/hour and desolvation gas flow was 650 L/h. The analytes and
their corresponding internal standards were specifically monitored using
a pair value cone voltage (V)/collision energy (eV) set at 55/36 and
22/12 for dapivirine and darunavir, respectively. Monitored MRM transi-
tions were m/z 330.13/158.06, 341.16/168.08, 548.20/392.20 and
557.20/401.20 for dapivirine, dapivirine-d11, darunavir and darunavir-d9,
respectively. Each transition was alternately monitored with a dwell time
of 0.04 s while quadrupole resolution in both Q1 and Q3 was set at 0.7
FWHM. Under these UPLC-MS/MS conditions, dapivirine/dapivirine-d11
and darunavir/darunavir-d9 displayed mean retention times of 2.8 and
2.4 min, respectively.
Pre- and post-use content of dapivirine
and darunavir rings
The initial and residual dapivirine and darunavir content of rings was
quantified following manufacture and after completion of both in vitro
release and in vivo pharmacokinetic testing in macaques (n¼4). Rings
were cut into pieces of 2 mm diameter and placed into a glass
flask. Dichloromethane (95 mL) was added along with 5 mL of a 1 or
2 mg/mL solution of 19-norethindrone (depending on the initial drug load-
ing in the ring) in methanol as internal standard. The flasks were sealed
and placed in an orbital incubator (Infors HT Unitron, Switzerland; 378C,
Table 2. Timepoints for collection of biological samples from macaques
during period of ring placement
Sampling procedure
Time after ring insertion (days)
0 0.3 1 2 7 14 21 28
Vaginal fluid (for drug quantification) x x x x x x x
Blood (for drug serumquantification) x x x x x x x
Blood for progesterone
quantification
x x x x x
Blood (for blood cell formula testing) x x x x
Tissue (for drug quantification) x
A combination microbicide vaginal ring
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60 rpm, throw 25 mm) for 72 h. One or two millilitres of the extraction
mixture (again, dependent upon drug loading) was transferred to a
boiling tube and evaporated to dryness. The residue was reconstituted in
10 mL of methanol with vortex mixing for 30 s and sonication for 20 min
to ensure complete drug dissolution. Samples were analysed by HPLCwith
detection by UV absorbance at 257 nm. A 10 mL aliquot of each sample
was injected onto a Phenomenexw Luna 5 mm C18(2) 100 A˚ column
(150×4.6 mm; Phenomenex, Cheshire, UK) held at 308C. HPLC was con-
ducted in isocratic mode with a mobile phase of HPLC-grade water
(25%) and HPLC-grade methanol (75%) at a flow rate of 0.75 mL/min.
Under these conditions dapivirine, darunavir and norethindrone had
mean retention times of 9.5, 3.5 and 5.1 min, respectively.
Ex vivo challenge studies on vaginal fluid samples
Vaginal fluid samples from the macaque pharmacokinetic study were
extracted into 60% acetonitrile containing 0.04% ammonium hydroxide
in water and shipped on dry ice to Janssen Diagnostics for in vitro testing
of antiretroviral compound activity. The MT4-CCR5high-LTR-eGFP cell
line (overexpression of CCR5 co-receptor) was kindly provided by
Dr Olivia Goethals (Janssen Infectious Diseases and Vaccines). Cells were
maintained in RPMI 1640 medium (Lonza) supplemented with 10%
FetalClonew II serum (Sigma), 0.04% gentamicin (Gibco) and 1%
Geneticin (Gibco) in a humidified incubator at 378C, 4.5% CO2. BaL virus
(CCR5-tropic HIV-1 strain) was supplied by Advanced Biotechnologies
Inc. Antiretroviral activity was determined using a cell-based HIV-1
green fluorescent protein reporter assay. A 3-fold dilution series of the
extracted samples in culture medium (without Geneticin, supplemented
with 2% DMSO) was made in 96-well plate format, with compound dilu-
tion determined based on the initial ring loading. MT4-CCR5high-LTR-eGFP
cells (75 mL/well) and BaL virus (75 mL/well) were added to the dilution
plate (50 mL/well) with a multiplicity of infection of 0.0025. By means of
a liquid handler (MICROLABw STAR; Hamilton Robotics) the 96-well assay
plate was transferred to a 384-well plate (40 mL/well) for readout after
3–4 days storage. Infection of MT4-CCR5high-LTR-eGFP cells with BaL
virus causes activation of the long terminal repeat promoting expression
of enhanced green fluorescent protein. The fluorescence signal was mea-
sured with a fluorescence scanning microscope (Axio Vert.A1, Zeiss). The
extent of inhibition of viral infection was determined as the level of fluor-
escence measured relative to positive controls (cells with virus, no ARVs
added) correcting for basal levels observed (cells with no virus or ARVs
added). Dose–response curves and IC50 values were calculated using
GraphPad Prism.
Statistical analyses
Where appropriate, results were statistically analysed using a one-way
analysis of variance, followed by post hoc analysis using the Tukey–
Kramer multiple comparisons test. In all cases, a P value of ,0.05 was
considered significant. Analysis was conducted using GraphPad Prism.
Results and discussion
DSC data
DSC thermograms and data obtained from the various dapivirine/
darunavir solid mixtures are presented in Figure 1(a) and Table 3,
respectively. Dapivirine showed a primary crystalline melting
transition at 2208C (Table 3, Peak 2).11,19 The endothermic transi-
tion at 1018C in the dapivirine thermogram has been observed
previously and represents the thermal transformation between
dapivirine crystalline forms I and II.11 Darunavir showed a thermal
transition around 1008C, caused by desolvation (i.e. evaporation
of ethanol) from the crystalline form (darunavir is an ethanolate
pseudo-polymorph) and subsequent formation of the liquid drug
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Figure 1. (a) Overlaid DSC traces of dapivirine (DAP) and darunavir (DRV) mixed in varying proportions. (b) Plot illustrating the depression of DAP onset
melting temperature in the solid drug mixtures as a function of DRV concentration. (c) Overlaid DSC traces for 100 mg DAP ring and 100 mg
DAP+300 mg DRV ring.
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form.20 At intermediate compositions, the darunavir melting
temperature remained unchanged while the dapivirine melting
temperature decreased and the melting endotherm peak broa-
dened in proportion to increasing concentrations of darunavir in
themixture (Figure 1a and Table 3). The dapivirine thermal behav-
iour is attributed to the entropy-driven phenomenon of melting
point depression (Figure 1b) associated with addition of a liquid
impurity (i.e. the melted, desolvated form of darunavir). Melting
point depression in two- (or multi-) component systems is directly
attributed to intermolecular interactions. Often, these intermo-
lecular interactions are hydrogen bonds, which are believed to
be highly significant in melting point depression.21 It has already
been established that dapivirine forms two hydrogen bonds with
Lys101 at the HIV-1 reverse transcriptase binding site and exhibits
strong p-p stacking or H . . . p interaction with Tyr181 and Tyr188
residues. These interactions play a vital role in stabilizing the
dapivirine+enzyme complex.22 Based on these data, it is likely
that the melting point depression for the dapivirine/darunavir
system is attributed to hydrogen bonding, since both molecules
have considerable scope for this type of intermolecular bonding.
Silicone elastomer samples containing various concentrations
of either dapivirine or darunavir alone showed endothermic peaks
at the normal crystalline melting temperature for each drug, and
with peak areas (enthalpy values) correlating with the drug
loading. By way of example, a 100 mg dapivirine ring sample is
presented in Figure 1(c). A silicone elastomer sample prepared
with dapivirine and darunavir concentrations equivalent to
those in the 100 mg dapivirine+300 mg darunavir macaque
ring [5.88% and 17.6% (w/w), respectively] showed the normal
melting endotherm for darunavir. However, the normally sharp
dapivirine crystalline melting transition at 2208C was not
observed, being replaced by a broader melting endotherm at
150–2008C (Figure 1c), similar to that observed for the solid
drug mixtures (Figure 1a).
A number of combination drug products are deliberately
formulated such that themelting point of each drug in the system
is depressed compared with the original drug material. Often, the
final drug ratio is selected to correspond to the minimummelting
temperature in the temperature–composition phase diagram,
since this so called eutectic composition leads to increased solu-
bility of each drug (and therefore improved release/dissolution).
EMLAw cream (a eutectic mixture of lidocaine and prilocaine)
and Nuvaringw (a combination contraceptive vaginal ring)
represent two examples of marketed drug products formulated
using a eutectic mixture of two different drug molecules. In the
absence of other degradative drug–drug interactions, eutectic
(or decreased melting temperature) systems do not pose any
additional manufacturing or stability issues for pharmaceutical
products.
In vitro release of dapivirine and darunavir from
vaginal rings
In vitro daily and cumulative release profiles for dapivirine and
darunavir from the various rings into IPA/water are presented in
Figure 2. Typical of matrix-type rings, release is high on day
1 and decreases on each subsequent day (Figure 2a and b). For
both drugs, in vitro release obeyed t
1
2 kinetics, as evidenced by lin-
ear cumulative release versus root time plots (Figure 2c and d;
R2.0.994, Table 4) and indicating a permeation-controlled drug
release mechanism from a polymeric matrix device containing
dispersed solid drug(s).23,24 For the dapivirine-only rings, increas-
ing the dapivirine loading from 25 to 100 mg significantly
increased the dapivirine release rate from 1511 to 3464 mg/day
1
2
(Figure 2a and c and Table 4), in accordance with well-established
mathematical models for these drug-in-polymer systems.23,24
The additional presence of 300 mg darunavir in the combination
ring further significantly enhanced the dapivirine release rate to
4201 mg/day
1
2 (Table 4). This enhancement may be attributed
to the darunavir-induced depression of the dapivirine melting
temperature (see DSC data), which would theoretically increase
dapivirine solubility in the system and its subsequent release
rate, and/or the formation of permeation channels in the silicone
elastomermatrix resulting from release of the higher concentration
darunavir component from the ring.25 Release enhancement is
also observed for darunavir when 100 mgdapivirine is incorporated
Table 3. Summary data obtained from DSC thermograms (data are means+SD; n≥4)
Dapivirine
fraction
Peak 1 Peak 2
onset
temperature (8C)
peak
temperature (8C) enthalpy (J/g)
onset
temperature (8C)
peak
temperature (8C) enthalpy (J/g)
1.00 101.27+0.08 104.76+0.07 9.98+0.44 219.64+0.07 221.78+0.36 111.70+1.60
0.90 99.31+0.09 103.58+0.08 18.99+1.62 210.88+1.02 218.05+0.41 84.17+2.92
0.80 97.81+0.17 103.47+0.34 25.71+3.06 206.58+3.05 213.16+0.55 68.84+9.76
0.70 97.57+0.11 104.68+0.25 44.88+2.51 196.94+0.82 208.85+0.80 49.71+5.56
0.60 96.69+0.50 104.80+0.60 53.20+7.55 191.66+5.66 202.93+1.95 45.57+3.59
0.50 95.98+1.20 104.25+0.47 72.47+5.64 174.01+2.31 194.84+1.18 28.71+4.96
0.40 100.12+0.26 106.09+0.27 79.42+4.21 165.26+8.12 184.84+1.24 18.86+2.95
0.30 96.83+1.39 105.53+1.02 83.86+3.40 153.15+4.90 174.86+3.48 9.22+1.73
0.20 101.47+1.70 106.60+0.62 92.10+13.39 142.20+9.48 159.20+4.69 8.21+2.25
0.10 99.40+0.32 106.32+0.48 115.70+5.84 151.42+6.73a 158.42+4.10a 1.06+0.80a
0.00 99.10+2.96 105.60+0.62 95.26+10.10 — — —
aThese values are less accurate due to limits in instrument sensitivity.
A combination microbicide vaginal ring
2481
JAC
 at Queen's University Belfast on September 10, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
into the ring (Figure 2b and d and Table 4). Based on the DSC data
presented earlier, this darunavir enhancement cannot be attribu-
ted to reduced darunavir melting temperature (since none was
observed); therefore, creation of permeation channels is assumed.
In summary, for the IPA/water release experiments, the addition of
300 mg darunavir to a 100 mg dapivirine ring results in a 21.2%
increase in the dapivirine release rate (Figure 2c and Table 4),
while the addition of 100 mg dapivirine to a 300 mg darunavir
ring produces a 42.5% increase in the darunavir release rate
(Figure 2d and Table 4). In vitro release of dapivirine and darunavir
into SVF (Figure 3) highlights the extent to which drug solubility in
the surrounding fluid controls release from a ring; both drugs are
poorly water soluble, such that release into SVF is significantly
less than that into IPA/water. However, it is interesting to note
that dapivirine release into SVF is significantly increased upon
increasing the drug loading from 25 mg to 100 mg (irrespective
of whether darunavir is present or not). Based on dapivirine aque-
ous solubility values (2.5 mg/mL in pH 4 buffer and .1 mg/mL in
water; R. K. Malcolm, unpublished data), the mean day 1 release of
dapivirine (179 mg) from the 100 mg ring is likely very close to the
solubility limit of dapivirine in SVF. In fact, for all dapivirine rings
released into SVF, sink conditions (underwhich drug concentrations
are not permitted to exceed 10% of saturation solubility) are prob-
ably not in operation.
Pharmacokinetic studies in cynomolgus macaques
Three different ring formulations were tested for pharmacokinetics
in macaques: 25 mg dapivirine-only ring, 100 mg dapivirine+300
mgdarunavir ring, and 300 mgdarunavir-only ring. The concentra-
tion versus time plots for dapivirine and darunavir in serum and
vaginal fluid during the 28 day period of ring placement are pre-
sented in Figure 4. Pharmacokinetic parameters for dapivirine and
darunavir in serum and vaginal fluid are summarized in Table 5.
Initial serum concentrations for both ARVs were 102 pg/mL,
similar to plasma concentrations previously measured in
women using dapivirine rings.2 Dapivirine serum concentrations
were maintained at these levels throughout the entire period of
ring use (Figure 4a), while darunavir concentrations decreased
slightly over time (Figure 4b). Dapivirine serum concentrations
were similar for the 25 mg dapivirine-only ring and the 100 mg
dapivirine+300 mg darunavir ring; darunavir serum concentra-
tions were consistently higher for the 100 mg dapivirine+300 mg
darunavir ring compared with the 300 mg darunavir-only ring,
although the differences were not always statistically significant.
Dapivirine concentrations in vaginal fluid were maintained within
the range 2×103–2×104 ng/g over the study period, with concen-
trations consistently (but not always significantly) higher for the
100 mg dapivirine-loaded combination ring (Figure 4c). Human
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Figure 2. Daily in vitro release versus time (a and b) and cumulative in vitro release versus root time (c and d) profiles for dapivirine (DAP) and darunavir
(DRV) into 100 mLof IPA/watermixture (1:1) over 28 days from a 25 mgDAP ring, a 300 mgDRV ring and a combination ring containing 100 mgDAPand
300 mg DRV. Each value is the mean of four replicates and error bars denote standard deviations.
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vaginal fluid concentrations for 25 mg dapivirine matrix and
25 mg dapivirine reservoir-type rings have previously been
reported as ranging from 4×103 to 3×106 ng/g.2 These higher
dapivirine concentrations are likely attributed to use of a different
type of silicone elastomer system and the larger size (and there-
fore greater surface area for drug release) of the human-sized
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Figure 3. Daily in vitro release versus time (a and b) and cumulative in vitro release versus root time (c and d) profiles for dapivirine (DAP) and darunavir
(DRV) into 100 mLof SVFover 28 days from a 25 mg DAP ring, a 100 mg DAP ring, a 300 mg DRV ring and a combination ring containing 100 mg DAP and
300 mg DRV. Each value is the mean of four replicates and error bars denote standard deviations.
Table 4. Summary in vitro release data for dapivirine (DAP) and darunavir (DRV) for the various silicone elastomer ring formulations into 1:1 IPA/water
mixture and SVF release media
Ring formulation Drug Release medium Release rate (mg/day
1
2) R2 value
25 mg DAP DAP IPA/water 1511 0.9998
100 mg DAP DAP IPA/water 3464 0.9998
100 mg DAP+300 mg DRV DAP IPA/water 4201 0.9999
300 mg DRV DRV IPA/water 430.4 0.9942
100 mg DAP+300 mg DRV DRV IPA/water 613.4 0.9988
25 mg DAP DAP SVF 196.8 0.9702
100 mg DAP DAP SVF 365.6 0.9980
100 mg DAP+300 mg DRV DAP SVF 361.0 0.9979
300 mg DRV DRV SVF 197.4 0.9988
100 mg DAP+300 mg DRV DRV SVF 181.1 0.9968
Release rates are the gradients obtained from linear regression analysis of the mean cumulative release versus root time plots (Figures 1c, d, 2c and d).
R2 values, representing the Pearson coefficient of determination, are also reported for the root time plots; values close to unity demonstratematrix-type
root-time release kinetics.
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rings (56 mm outer diameter, 7.6 mm cross-sectional diameter).
However, they might also be attributed to the different pH
environments in human (pH 4.5) and macaque (pH 7) vaginas;
dapivirine is a weak base (pKa¼5.54 at 258C26) and therefore is
present mostly in its protonated form at human vaginal pH,
whereas the free base form predominates at macaque vaginal
pH. Darunavir concentrations tended to decrease with time
(Figure 4d), ranging from 7×104 ng/g at 8 h after ring placement
to 9×103 ng/g on day 28. Maximum or near-maximum vaginal
fluid and serum concentrations for dapivirine and darunavir
were mostly observed at or close to the initial 8 h sampling time-
point, indicating relatively rapid release of the drugs from the rings
and subsequent absorption.
The range of dapivirine and darunavir concentrations mea-
sured in the various macaque tissues following necropsy on
day 28 decreased according to the following rank order: vagina
(1.8×103–3.8×103 ng/g) .cervix (9.4×101–3.9×102 ng/g) .
uterus (0–108 ng/g) .rectum (0–40 ng/g) .axillary lymph
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Figure 4. Serum (a and b) and vaginal fluid (c and d) concentration versus time profiles for dapivirine (DAP) and darunavir (DRV) during 28 day placement
in cynomolgus macaques of silicone elastomer matrix-type rings containing 25 mg DAP, 300 mg DRV and a combination of 100 mg DAP and 300 mg
DRV. Each value is the mean of four replicates and error bars denote standard deviations.
Table 5. Statistical pharmacokinetic parameters for dapivirine (DAP) and darunavir (DRV) in macaque serum and vaginal fluid following placement of
vaginal rings containing 25 mg DAP, 300 mg DRV and 100 mg DAP+300 mg DRV
Drug Ring formulation
Vaginal fluid Serum
Cmax (ng/g) Tmax
a (h) AUC (mg.h/g) Cmax (pg/mL) Tmax
a (h) AUC (pg.h/mL)
DAP 25 mg DAP 7591+2508 168 3336+854 250+150 48 74851+35024
DAP 100 mg DAP+300 mg DRV 19260+5675 8 6336+3999 206+108 108b 100945+51871
DRV 300 mg DRV 50650+12425 8 10508+1996 101+33 24 27612+12201
DRV 100 mg DAP+300 mg DRV 69916+11798 8 15863+11401 178+116 24 43009+16236
aThe most common point reporting the maximum concentration.
bNo timepoint was most common; value reported is the mean of the two middle timepoints.
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nodes (0–8 ng/g) . iliac lymph node (no drug levels detected;
Figure 5). The greater drug concentrationsmeasured in the vagina
relative to the cervix were consistent with the observation follow-
ing necropsy that rings were located in the mid-vagina; by com-
parison, additional studies with smaller rings (20×4.5 mm) are
ongoing and clearly show the smaller ring located close to the
cervix. The relatively high drug concentrations in both the vagina
and cervix are important, since these tissues are implicated as
the primary infection sites for sexual transmission of HIV-1. In
fact, the highest concentration of HIV-infectable cells (i.e. CD4+
T lymphocytes, macrophages and Langerhans cells) in the female
genital tract are found in the cervical tissue, with significantly
lower numbers found in the vaginal tissue.27 Approximately
2-fold higher dapivirine concentrations have previously been
measured in vaginal tissue biopsies sampled adjacent to the
ring location compared with ectocervical tissue biopsies for
two different reservoir-type rings in humans.3 The detection of
dapivirine and darunavir in non-vaginal tissues is attributed to
passive diffusion, although darunavir concentrations in the uterus
(dapivirine was not measured in the uterus) may also have
resulted from a first uterine pass effect.28,29 We have recently
reported both vaginal-to-rectal and rectal-to-vaginal transfer of
CMPD167, an experimental entry inhibitor antiretroviral drug, fol-
lowing vaginal administration of gels and rings and rectal gel
administration.30 Dapivirine and darunavir tissue concentrations
did not vary significantly across the different ring formulations,
although some general trends (and exceptions) can be observed.
For example, dapivirine concentrations in vaginal and cervical
tissues (Figure 5) were generally 2-fold greater for the combin-
ation ring (containing 100 mg dapivirine) compared with the
25 mg dapivirine-only ring, perfectly reflecting the prediction
based on the Higuchi equation that a 4-fold increase in drug
loading is required to double the drug release rate in a
permeation-controlled matrix-type drug delivery system.23,31
Also, concentrations of darunavir in the vaginal and cervical tis-
sues were generally higher for the combination ring (containing
300 mg darunavir) compared with the 300 mg darunavir-only
ring, mimicking the in vitro release data into IPA/water
(Figure 2d) and suggesting that incorporation of dapivirine
increases the darunavir release rate.
Endogenous serum progesterone concentrations were also
measured at various timepoints (Table 2) during ring placement
to determine the stage of menstrual cycle for each macaque
(data are presented in the Supplementary information). Generally,
the follicular and luteal phases were readily identified by progester-
one serum levels of ,1 and 2–15 ng/mL, respectively (Figure S1
and Figure S2, both available as Supplementary data at JAC
Online). There was no obvious correlation between the stage
of menstrual cycle and drug concentrations in vaginal fluid
(Figure S1 and Figure S2) or serum (data not shown). Exogenous
progestin administration, in the form of subcutaneously adminis-
teredmedroxyprogesterone acetate (Depo-Provera), has previously
been shown to significantly influence the pharmacokinetics of
antiretroviral-releasing vaginal rings in macaques.9
Ex vivo activity of dapivirine and darunavir against
HIV challenge
IC50 values calculated against HIV-1 BaL from samples taken at
each timepoint are displayed in Figure 6 for all of the rings.
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Mean IC50 values for dapivirine from the 25 mg dapivirine ring
ranged from 0.09 to 0.14 ng/mL (two samples excluded because
of ambiguous values). On average, dapivirine concentrations in
vaginal fluid were .15000-fold greater than the calculated IC50
value (ng/mL) during the 28 day study period. However, because
of the relatively small pre-dilution step (1:3), solvent effects on
the dose–response curve cannot be excluded and hence the
calculated IC50 value should be viewed with caution. Several of
the samples from the 300 mg darunavir ring study provided
ambiguous IC50 values or failed to provide an appropriate
dose–response curve. Mean IC50 values calculated on samples
taken at 8 h and 7 days ranged from 1.36 to 1.86 ng/mL. Over
this time period the darunavir concentration in vaginal fluid was
.17000-fold the calculated IC50 value. However, the data from
samples taken outside this time frame did not allow for robust
IC50 value determination. Mean IC50 values calculated for the
combination ring ranged from 0.28 to 1.31 ng/mL. On average,
the dapivirine and darunavir concentrations in vaginal fluid (ng/g)
were .20000-fold the determined IC50 values over the 28 day
study period. Note that the IC50 calculated for the combination
dapivirine+darunavir ring reflects the combined compound con-
centration of dapivirine and darunavir within the extracted vaginal
fluid sample.
In general, the data support the activity of both drugs when
present in vaginal fluid at sufficient concentration. However, the
methodology required to effectively extract and process these
highly hydrophobic drugs, and dapivirine in particular, reduces
the accuracy of these measurements owing to the presence of
residual organic solvent in the test sample. Further work is
required to develop a method that would allow for compound
testing in the in situ vaginal fluid, particularly for highly hydropho-
bic compounds with relatively poor aqueous solubility like many
experimental NNRTIs.
Residual dapivirine and darunavir in vaginal rings
The quantities of dapivirine and darunavir released from the rings
during in vitro release testing and pharmacokinetic testing in
macaques were calculated according to the equation Q¼L2R,
where Q is the quantity of drug released, L is the initial drug load-
ing and R is the residual drug content. L was determined for a
sample (n¼4) of rings immediately after manufacture using the
previously described solvent extraction method, and the value
was assumed to apply to all other rings within the same batch.
R was also determined using the solvent extraction method for
rings (n¼4 per set) following completion of in vitro release and
pharmacokinetic testing. Given that L values could not be deter-
mined for the rings that underwent testing (due to the destructive
nature of the content determination method), the Q values
reported in Table 6 are considered approximate. For both anti-
retroviral drugs, in vitro release into IPA/water was significantly
greater than into SVF, reflecting the poor aqueous solubility of
dapivirine and darunavir. In the macaque pharmacokinetic stud-
ies, the quantity of dapivirine administered was greater for the
Table 6. Quantity of dapivirine (DAP) and darunavir (DRV) released from vaginal rings during in vitro release testing and in vivo pharmacokinetic (PK)
studies in macaques
Ring formulation
Dapivirine Darunavir
in vitro release testing
PK study
in vitro release testing
PK studyIPA/water SVF IPA/water SVF
25 mg DAP 7.89+0.04 0.88+0.01 0.66+0.39 — — —
100 mg DAP+300 mg DRV 21.48+0.07 1.70+0.01 12.62+1.68 3.19+0.16 0.86+0.13 27.41+4.82
300 mg DRV — — — 2.14+0.06 0.96+0.19 36.04+6.56
In vitro release testing values are presented as the mean cumulative release (+SD) of rings (n¼4) into IPA/water and SVF. PK study values represent
mean amounts of drug released (n¼4;+SD). These valueswere calculated from residual content values determined using solvent extraction subtracted
from a mean batch content determination conducted on rings manufactured in the same batch. The standard deviation is that of the four determined
residual content values and does not consider the variation in initial content of the manufactured rings. All values are quoted in mg.
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higher-loaded combination ring (12.62+1.68 mg) comparedwith
the 25 mg dapivirine-only ring (0.66+0.39 mg), while the quan-
tity of darunavir administered was not significantly different
between the 300 mg darunavir and 100 mg dapivirine+300 mg
darunavir rings.
Given that a 25 mg dapivirine-only silicone elastomer vaginal
ring is currently being tested in Phase III human clinical studies,
and based on the supposition that combination antiretroviral
microbicides targeting different stages of the HIV-1 replication
cycle are likely to provide increased breadth and degree of protec-
tion against vaginal HIV transmission compared with single active
molecules, we conclude that the results of this study strongly
support progress of a combination dapivirine+darunavir silicone
elastomer vaginal ring into early stage clinical studies. The poten-
tial of protease inhibitors as vaginal microbicides, either alone or
in combination, also warrants further investigation.
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